| __timestamp | Iovance Biotherapeutics, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 2652041 |
| Thursday, January 1, 2015 | 12390000 | 2361587 |
| Friday, January 1, 2016 | 25602000 | 4472869 |
| Sunday, January 1, 2017 | 21262000 | 5030957 |
| Monday, January 1, 2018 | 28430000 | 4988941 |
| Tuesday, January 1, 2019 | 40849000 | 5196412 |
| Wednesday, January 1, 2020 | 60210000 | 6652774 |
| Friday, January 1, 2021 | 83664000 | 18418247 |
| Saturday, January 1, 2022 | 104097000 | 24827066 |
| Sunday, January 1, 2023 | 106916000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Infusing magic into the data realm
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Opthea Limited and Iovance Biotherapeutics, Inc., from 2014 to 2023.
Iovance Biotherapeutics, Inc. has shown a significant upward trend in SG&A expenses, increasing by over 1,000% from 2014 to 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Opthea Limited's SG&A expenses have grown by approximately 1,500% during the same period, indicating a robust scaling strategy.
The year 2023 marked a peak for both companies, with Iovance's expenses reaching their highest at over $106 million, while Opthea's expenses surged to nearly $42 million. Notably, 2024 data for Iovance is missing, suggesting a potential shift or strategic change.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Opthea Limited
Opthea Limited or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Opthea Limited and Merus N.V.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Opthea Limited vs MorphoSys AG Trends and Insights
Cost Management Insights: SG&A Expenses for Opthea Limited and Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Opthea Limited vs Geron Corporation
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?